

The Medical Letter[®]

on Drugs and Therapeutics

Volume 60

June 18, 2018

ISSUE No.

1549

IN THIS ISSUE

In Brief: Pitavastatin Magnesium (*Zypitamag*) for Hyperlipidemiap 106

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 60 (Issue 1549)

June 18, 2018

Take CME Exams

IN BRIEF

Pitavastatin Magnesium (*Zypitamag*) for Hyperlipidemia

The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (*Zypitamag* – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium (*Livalo*), which was approved in 2009.¹

Pronunciation Key
Zypitamag: zai pit' a mag"

Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in patients

with or at high risk for atherosclerotic cardiovascular disease.² Even in patients at low risk for cardiovascular disease, treatment with a statin can significantly reduce the incidence of cardiovascular events.³

Controlled trials in patients with cardiovascular disease have shown that high-intensity statin therapy (defined as reducing LDL-cholesterol [LDL-C] by $\geq 50\%$ on average) reduces the incidence of cardiac events, stroke, and coronary death significantly more than less intensive regimens. In one meta-analysis, each additional 1 mmol/L (39 mg/dL) reduction in LDL-C was associated with a 20% reduction in major vascular events and a 10% reduction in all-cause mortality.⁴ In a randomized trial in 13,054 Japanese patients with stable coronary artery disease, over a median follow-up of 3.9 years, patients taking pitavastatin calcium 4 mg daily were significantly less likely than those taking 1 mg daily to have a cardiovascular event (4.3% vs 5.4%).⁵

Table 1. Statins

Drug	Some Formulations	Usual Adult Dosage ¹	Average LDL-C Reduction ²	Cost ³
Atorvastatin – generic <i>Lipitor</i> (Pfizer)	10, 20, 40, 80 mg tabs	Initial: 10-20 mg once/d Maximum: 80 mg once/d	35-40% 50-60%	\$11.00 299.40
Fluvastatin – generic <i>Lescol</i> (Novartis)	20, 40 mg caps	Initial: 40 mg bid Maximum: 40 mg bid	20-25% 30-35%	239.80 305.50
extended-release – generic <i>Lescol XL</i>	80 mg tabs	Initial: 80 mg once/d Maximum: 80 mg once/d	35-38%	199.50 323.00
Lovastatin – generic	10, 20, 40 mg tabs	Initial: 20 mg once/d Maximum: 80 mg once/d ⁴	25-30% 35-40%	6.70
extended-release – <i>Altoprev</i> (Watson/Actavis)	20, 40, 60 mg tabs	Initial: 20 mg once/d Maximum: 60 mg once/d	20-25% 40-45%	877.20
Pitavastatin – <i>Livalo</i> (Kowa) ⁵ <i>Zypitamag</i> (Zydus) ⁵	1, 2, 4 mg tabs	Initial: 2 mg once/d Maximum: 4 mg once/d	35-40% 40-45%	276.30 232.50
Pravastatin – generic <i>Pravachol</i> (BMS)	10, 20, 40, 80 mg tabs	Initial: 40 mg once/d ⁶ Maximum: 80 mg once/d	30-35% 35-40%	21.60 169.70
Rosuvastatin – generic <i>Crestor</i> (AstraZeneca)	5, 10, 20, 40 mg tabs	Initial: 10-20 mg once/d ^{7,8} Maximum: 40 mg once/d ⁹	45-50% 50-60%	8.30 260.90
Simvastatin – generic <i>Zocor</i> (Merck)	5, 10, 20, 40, 80 mg tabs	Initial: 10-20 mg once/d ¹⁰ Maximum: 40 mg once/d ^{11,12}	35-40% 45-50%	3.80 138.60

1. FDA-approved dosage. Some expert clinicians use lower doses for initial treatment of patients with only modest elevations of LDL-C or a history of poor tolerance to these drugs. For patients who require a large reduction in LDL-C, some would use higher doses initially. Statins are generally most effective when taken in the evening. Dosage adjustment may be needed for patients with renal or hepatic impairment.
2. The listed ranges correspond to the initial and maximum dosages. Statin dosages that lower LDL-C by $\geq 50\%$ are considered high-intensity therapy. Those that lower LDL-C by 30--50% are considered moderate-intensity therapy. LDL-C reductions may vary significantly among individuals.
3. Approximate WAC for 30 days' treatment at the lowest initial dosage unless otherwise specified. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. www.fdbhealth.com/policies/drug-pricing-policy.
4. Or 40 mg bid.
5. *Livalo* is the calcium salt of pitavastatin and *Zypitamag* is the magnesium salt of pitavastatin. Although equivalent strengths of *Livalo* and *Zypitamag* contain the same amount of pitavastatin base, the drugs are not interchangeable.
6. 10 mg initially for patients with significant renal impairment.
7. Higher serum concentrations of rosuvastatin have been reported in Asian patients; an initial dose of 5 mg once/day is recommended.
8. Patients with severe renal impairment not on hemodialysis should start with 5 mg and not exceed 10 mg/day.
9. Maximum dose is 20 mg/day in Asian patients (E Lee et al. Clin Pharmacol 2005; 78:330).
10. Patients with severe renal impairment should start with 5 mg.
11. Patients who have taken 80 mg/day of simvastatin for ≥ 12 months without evidence of myopathy can continue at this dose.
12. The maximum dose of simvastatin is 10 mg if taken with diltiazem or verapamil and 20 mg if taken with amiodarone, amlodipine, or ranolazine.

Approval of pitavastatin magnesium was based on the results of trials with pitavastatin calcium; no new efficacy trials were required. *The Medical Letter's* review of pitavastatin calcium concluded that recommended doses of the drug had not been shown to decrease LDL-C more than other statins with longer safety records and there was no good reason to use it. That conclusion applies to pitavastatin magnesium as well. ■

1. Pitavastatin (Livalo) – the seventh statin. *Med Lett Drugs Ther* 2010; 52:57.
2. Lipid-lowering drugs. *Med Lett Drugs Ther* 2016; 58:133.
3. CTT Collaboration et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012; 380:581.
4. CTT Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010; 376:1670.
5. I Taguchi et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. *Circulation* 2018; 137:1997.

Follow us on Twitter  Like us on Facebook 

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., F.R.C.P.C., F.R.S.C., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **ASSISTANT MANAGING EDITOR:** Liz Donohue

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **SITE LICENSE SALES:** Elaine Reaney-Tomaselli; **EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents, and
fellows in the US and Canada.
Reprints - \$25/article; \$35/issue

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:  

Copyright 2018. ISSN 1523-2859

The
Medical
Letter